Advertisement Pharmaceutical Business review - Page 506 of 5279 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 29, 2026

Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe

Eli Lilly and Company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.

Results from the BRUIN CLL-313 and BRUIN CLL-314 studies supported the application. Credit: Sai Thaw Kyar/Shutterstock.com.